TABLE OF CONTENTS:
I. NIDA Early Career Workshop. June 11, 2022 @ 1:00 pm - 2:30 pm EDT
-----
I. NIDA Early Career Workshop. June 11, 2022 @ 1:00 pm - 2:30 pm EDT
Register to attend the virtual workshop on Saturday, June 11
This zoom webinar symposium will focus on career transition and the independence of early investigators. The speakers will incorporate strategies for writing successful NIH grants applications among other advice for early career scientists. This symposium has been developed to address issues identified in a recent survey of early career investigators, graduate and postdoctoral fellows, early-stage investigators, and newly established faculty. This workshop is open to everyone, including non-registrants.
Agenda at Glance
13:00 EDT Welcome
13:10 EDT Launching Research Careers in Addiction Science
15:10 EDT Strategies Applicable in Career Development and Transition
15:30 EDT Adjourn
Register here: https://seiservices.zoom.us/webinar/register/WN_H_D2eWTQSHiQq5adYpDqGQ
II. Impact of Comorbid COVID-19 and Substance Use During Pregnancy on Fetal and Infant Development Workshop, NIDA Brain Development Research Consortium
Wednesday, July 20th, 10:00 am - 5:00 pm EDT
The workshop will include four sessions that cover: the impact of COVID infection (with attention to the variant) on the developing fetus, the impact of pandemic stress on maternal health, the impact of comorbid COVID-19 infection and/or pandemic stress and substance use on fetal outcomes and neurodevelopment, and innovations in remote data collection and telehealth born out of the pandemic. The workshop will establish the state of the science in efforts to understand gaps and opportunities for ongoing research.
For more information contact:
Da-Yu Wu, wudy@nida.nih.gov, 301.435.4649
Register here: Zoom https://seiservices.zoom.us/meeting/register/tZYvdOyqqjkrEtaUdU5J0gK1T9vuNYzEfRwc
III. Investigating Transposable Elements and Mobile DNA as Targets of Integration for Establishing HIV Reservoirs in the Brain (R61/R33 - Clinical Trial Optional) RFA-DA-23-003
The purpose of this funding opportunity announcement (FOA) is to support research examining the potential contributions of mobile DNA elements and addictive substances in HIV integration, reservoir formation, and maintenance in the brain. NIDA is specifically interested in studies exploring the contributions of molecular, genetic, and epigenetic factors in HIV integration, reservoir formation, and maintenance in microglia and/or the brain in the context of addiction.
https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-003.html
Letter of Intent due July 3, 2022 and applications are due Aug 3, 2022 5:00 PM local time of applicant organization.
IV. Pathogenic Mechanisms influencing Blood Brain Barrier function in HIV and Substance Use Disorders (R01 Clinical Trial Optional) RFA-DA-23-012
This Funding Opportunity Announcement (FOA) supports research on the effects of HIV and addictive substances, acting independently or synergistically on blood brain barrier (BBB) structure and function and the involvement of these effects in HIV associated neuropathology.
https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-012.html
Letter of Intent due July 11, 2022 and applications are due Aug 11, 2022 5:00PM local time of applicant organization.
V. A Multi-omics Approach to Immune Responses in HIV Vaccination and Intervention (P01 Clinical Trial Not Allowed) RFA-AI-22-038
National Institute of Allergy and Infectious Diseases
National Institute on Drug Abuse
The purpose of this Funding Opportunity Announcement (FOA) is to support multi-disciplinary, multi-component applications proposing the use of omics technologies to advance preventative and/or therapeutic vaccinations, and/or immunomodulatory cure interventions for HIV. Projects will integrate omics, computational, and hypothesis-driven experimental approaches to interrogate immune responses to HIV vaccination and/or cure strategies
https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-038.html
Letters of Intent due September 13, 2022 and applications are due October 13, 2022.
VI. Advancing technologies to improve delivery of pharmacological, gene editing, and other cargoes for HIV and SUD mechanistic or therapeutic research (R01- Clinical Trial Optional) RFA-DA-22-010
The purpose of this funding opportunity is to develop technologies to improve the delivery of pharmacological, gene editing, or other cargoes for HIV and SUD mechanistic research.
https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-010.html
Letter of Intent due September 25, 2022 and applications are due October 25, 2022.
VII. Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) PAR-19-223
Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies.
The Genetics or Epigenetics of Substance Use Disorders Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction. These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of addiction. Investigators outside the field of addiction interested in applying their novel approaches to the genetics or epigenetics of addiction are encouraged to apply. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field of genetics or epigenetics of substance use disorders.
https://grants.nih.gov/grants/guide/pa-files/PAR-20-225.html
Letter of Intent due September 19, 2022 and applications are due October 19, 2022.
The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L
No comments:
Post a Comment